{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:13Z","timestamp":1787008993998,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"Supplement_7","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1151153"],"award-info":[{"award-number":["OPP1151153"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 DK067872"],"award-info":[{"award-number":["T32 DK067872"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The disease burden of typhoid fever remains high in endemic areas in Asia and Africa, especially in children. Recent clinical trials conducted by the Typhoid Vaccine Acceleration Consortium show typhoid conjugate vaccine (TCV) to be safe, immunogenic, and efficacious at preventing blood culture-confirmed typhoid fever in African and Asian children. Pakistan, Liberia, and Zimbabwe recently introduced TCV through campaigns and routine childhood immunizations, providing protection for this vulnerable population. It is essential to continue this momentum while simultaneously filling data gaps\u2014including typhoid complications\u2014to inform decision-making on TCV introduction. A multidisciplinary approach including surveillance, water, sanitation, and hygiene investments, and large-scale TCV introduction is needed to decrease the burden and mortality of typhoid fever.<\/jats:p>","DOI":"10.1093\/infdis\/jiab449","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T15:37:54Z","timestamp":1631115474000},"page":"S781-S787","source":"Crossref","is-referenced-by-count":38,"title":["Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas"],"prefix":"10.1093","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5746-1321","authenticated-orcid":false,"given":"Megan","family":"Birkhold","sequence":"first","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziza","family":"Mwisongo","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH \u00a0, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Pollard","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom"},{"name":"National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M","family":"Neuzil","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"2021122015214512500_CIT0001","doi-asserted-by":"crossref","first-page":"e0008048","DOI":"10.1371\/journal.pntd.0008048","article-title":"Changes in historical typhoid transmission across 16 U.S. cities, 1889\u20131931: quantifying the impact of investments in water and sewer infrastructures","volume":"14","author":"Phillips","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2021122015214512500_CIT0002","author":"Global Burden of Disease Collaborative Network."},{"key":"2021122015214512500_CIT0003","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jinf.2020.10.030","article-title":"Complications and mortality of typhoid fever: a global systematic review and meta-analysis","volume":"81","author":"Marchello","year":"2020","journal-title":"J Infect"},{"key":"2021122015214512500_CIT0004","first-page":"346","article-title":"The global burden of typhoid fever","volume":"82","author":"Crump","year":"2004","journal-title":"Bull World Health Organ"},{"key":"2021122015214512500_CIT0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cid\/ciaa314","article-title":"Tenacious endemic typhoid fever in Samoa","volume":"71","author":"Sikorski","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021122015214512500_CIT0006","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/infdis\/jiy522","article-title":"Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP): an overview and lessons learned","volume":"218","author":"Barkume","year":"2018","journal-title":"J Infect Dis"},{"key":"2021122015214512500_CIT0007","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/cid\/civ675","article-title":"What have we learned from the typhoid fever surveillance in Africa program?","volume":"62","author":"Baker","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021122015214512500_CIT0008","doi-asserted-by":"crossref","first-page":"e0006779","DOI":"10.1371\/journal.pntd.0006779","article-title":"A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid","volume":"12","author":"Britto","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2021122015214512500_CIT0009","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018\u2014recommendations","volume":"37","author":"World Health Organization.","year":"2019","journal-title":"Vaccine"},{"key":"2021122015214512500_CIT0010","article-title":"Prospects of future typhoid and paratyphoid vaccines in endemic countries","author":"Shakya","journal-title":"J Infect Dis"},{"key":"2021122015214512500_CIT0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/cid\/ciy884","article-title":"Overview of the typhoid conjugate vaccine pipeline: current status and future plans","volume":"68","author":"Sahastrabuddhe","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021122015214512500_CIT0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021122015214512500_CIT0013","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"2021122015214512500_CIT0014","doi-asserted-by":"crossref","first-page":"e016283","DOI":"10.1136\/bmjopen-2017-016283","article-title":"The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys","volume":"7","author":"Darton","year":"2017","journal-title":"BMJ Open"},{"key":"2021122015214512500_CIT0015","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1016\/j.vaccine.2017.08.001","article-title":"The Typhoid Vaccine Acceleration Consortium (TyVAC): vaccine effectiveness study designs: accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26\u201327 October 2016, Oxford, UK","volume":"35","author":"Meiring","year":"2017","journal-title":"Vaccine"},{"key":"2021122015214512500_CIT0016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/cid\/ciy1106","article-title":"Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infections among Nepalese children: a protocol for a phase III, randomized control trial","volume":"68","author":"Theiss-Nyland","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021122015214512500_CIT0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cid\/ciy1103","article-title":"Typhoid vaccine acceleration consortium Malawi: a phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi","volume":"68","author":"Meiring","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021122015214512500_CIT0018","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cid\/ciy1107","article-title":"Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection among Bangladeshi children: a protocol for a phase IIIb trial","volume":"68","author":"Theiss-Nyland","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021122015214512500_CIT0019","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/cid\/ciy1104","article-title":"A phase II, randomized, double-blind, controlled safety and immunogenicity trial of typhoid conjugate vaccine in children under 2 years of age in Ouagadougou, Burkina Faso: a methods paper","volume":"68","author":"Laurens","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021122015214512500_CIT0020","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122015214512500_CIT0021","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of typhoid conjugate vaccine in Malawian children","author":"Patel","year":"2021","journal-title":"N Engl J Med"},{"key":"2021122015214512500_CIT0022","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"Lancet"},{"key":"2021122015214512500_CIT0023","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijid.2020.10.103","article-title":"Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15","volume":"102","author":"Sirima","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2021122015214512500_CIT0024","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijid.2021.05.061","article-title":"Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial","volume":"108","author":"Sirima","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2021122015214512500_CIT0025","first-page":":45\u201352","article-title":"Global advisory committee on vaccine safety, 5\u20136 December 2018","volume":"94","author":"World Health Organization.","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"key":"2021122015214512500_CIT0026","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1473-3099(19)30425-6","article-title":"Typhoid Vi-conjugate vaccine for outbreak control in Zimbabwe","volume":"19","author":"Olaru","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021122015214512500_CIT0027","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1016\/S2214-109X(21)00255-2","article-title":"Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study","volume":"9","author":"Yousafzai","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2021122015214512500_CIT0028","author":"Oberman","year":"2021"},{"key":"2021122015214512500_CIT0029","first-page":"44","article-title":"Morbidity and mortality of typhoid intestinal perforation among children in sub-Saharan Africa 1995\u20132019: a scoping review","author":"Birkhold","year":"2020","journal-title":"World J Surg"},{"key":"2021122015214512500_CIT0030","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/cid\/ciaa405","article-title":"Intestinal perforations associated with a high mortality and frequent complications during an epidemic of multidrug-resistant typhoid fever in Blantyre, Malawi","volume":"71","author":"Olgemoeller","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab449\/40393995\/jiab449.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_7\/S781\/41826211\/jiab449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_7\/S781\/41826211\/jiab449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T10:24:09Z","timestamp":1639995849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/Supplement_7\/S781\/6370981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":30,"journal-issue":{"issue":"Supplement_7","published-online":{"date-parts":[[2021,9,16]]},"published-print":{"date-parts":[[2021,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab449","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,15]]},"published":{"date-parts":[[2021,9,16]]}}}